Top-News

Inventiva Aktie News

Aktie
WKN:  A2DLV9 ISIN:  FR0013233012 US-Symbol:  IVEVF Branche:  Biotechnologie Land:  Frankreich
3,50 €
-0,025 €
-0,71%
12:00:31 Uhr
Depot/Watchlist
Marktkapitalisierung *
294,77 Mio. €
Streubesitz
25,05%
KGV
-0,80
Index-Zuordnung
-

Inventiva News

28.11.25 - GlobeNewswire
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Daix (France), New York City (New York, United States), November 28, 2025  – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
24.11.25 - GlobeNewswire
Information relating to the stabilization activities carried out in the context of its recent offering
Daix (France), New York City (New York, United States), November 24, 202 5 – Publication of information relating to the stabilization activities carried out in the context of the recent ...
21.11.25 - GlobeNewswire
Inventiva reports 2025 Third Quarter Financial Information¹
Cash and cash equivalents at €97.6 million, and €24.7 million in short-​term deposits 2 as of September 30, 2025. Revenues of €4.5 million for the first nine months of 2025. Cash ...
17.11.25 - GlobeNewswire
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
13.11.25 - GlobeNewswire
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
12.11.25 - GlobeNewswire
Inventiva announces launch of public offering
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
06.11.25 - GlobeNewswire
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
Daix (France), New York City (New York, United States), November 6,  2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage ...
06.11.25 - GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as October 20, 2025
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www . i n v e n t i v a p ha r m a. c om Date Number ...
14.10.25 - GlobeNewswire
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage ...
07.10.25 - GlobeNewswire
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study Presentation of digital pathology data from preclinical ...
01.10.25 - GlobeNewswire
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Daix (France), New York City (New York, United States), October 1, 2025  – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
29.09.25 - GlobeNewswire
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update  
Cash and cash equivalents at €146.7 million including €24.6 million in short-​term deposits 1 as of June 30, 2025 Receipt of the gross proceeds of €115.6 million from the second ...
24.09.25 - GlobeNewswire
Inventiva to Host Analyst and Investor Event on October 8, 2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026 Three renowned ...
04.09.25 - GlobeNewswire
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-​stage ...
11.08.25 - GlobeNewswire
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
31.07.25 - GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage biopharmaceutical ...
29.07.25 - GlobeNewswire
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
Cash and cash equivalents at €122.1 million and €24.6 million in short-​term deposits 2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City ...
09.07.25 - GlobeNewswire
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, ...
07.07.25 - GlobeNewswire
Inventiva receives $10 million milestone payment from CTTQ
Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
02.07.25 - GlobeNewswire
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »